Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks By Investing.com
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks
Was macht Outlook Therapeutics?
Unternehmensprofil
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Chart der Outlook Therapeutics Aktie
Charttool öffnen
Aktuelle Nachrichten zu Outlook Therapeutics
Weitere Nachrichten
Das berichten andere über Outlook Therapeutics
Outlook Therapeutics stock plunges after FDA rejects wet AMD drug application By Investing.com
Outlook Therapeutics stock plunges after FDA rejects wet AMD drug application
Outlook Therapeutics Announces New Employment Inducement Grants
ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab...
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Live webcast on Wednesday, January 29th at 2:00 PM ET Live webcast on Wednesday, January 29th at 2:00 PM ET
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt
und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.